Hospital-wide SARS-CoV-2 antibody screening of 4840 staff members in a University Medical Center in France: a cross-sectional study.
COVID-19
infection control
occupational & industrial medicine
public health
virology
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
11 05 2022
11 05 2022
Historique:
entrez:
11
5
2022
pubmed:
12
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
Healthcare workers are more likely to be infected by SARS-CoV-2. In order to assess the infectious risk associated with working in a hospital, we sought to estimate the proportion of healthcare professionals infected with SARS-CoV-2 by screening staff in a University Medical Center in France. A hospital-wide screening campaign (comprising a serological test and a questionnaire) ran from 18 May to 26 July 2020. The seroprevalence rate was analysed in a multivariate analysis according to sociodemographic variables (age, sex and profession), exposure to SARS-CoV-2 and symptoms. A total of 4840 professionals were included, corresponding to 74.5% of the centre's staff. The seroprevalence rate (95% CI) was 9.7% (7.0% to 12.4%). Contact with a confirmed case of COVID-19 was significantly associated with seropositivity (OR (95% CI: 1.43, (1.15 to 1.78)). The seroprevalence rate was significantly higher among nursing assistants (17.6%) than among other healthcare professionals. The following symptoms were predictive of COVID-19: anosmia (OR (95% CI): 1.55, (1.49 to 1.62)), ageusia (1.21, (1.16 to 1.27)), fever (1.15, (1.12 to 1.18)), myalgia (1.03, (1.01 to 1.06)) and headache (1.03, (1.01 to 1.04)).
Identifiants
pubmed: 35545377
pii: bmjopen-2020-047010
doi: 10.1136/bmjopen-2020-047010
pmc: PMC9096052
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e047010Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
JAMA. 2020 Sep 1;324(9):893-895
pubmed: 32780804
PLoS One. 2020 Dec 28;15(12):e0244348
pubmed: 33370363
Int J Epidemiol. 2021 May 17;50(2):400-409
pubmed: 33434269
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Infect Control Hosp Epidemiol. 2021 Feb;42(2):212-214
pubmed: 32746953
J Hosp Infect. 2020 Sep;106(1):102-106
pubmed: 32593608
Vaccines (Basel). 2021 Jul 27;9(8):
pubmed: 34451949
J Infect. 2021 Jan;82(1):e29-e32
pubmed: 33010259
Clin Chem Lab Med. 2020 Aug 26;58(12):2107-2111
pubmed: 32845861
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
J Infect. 2021 Jan;82(1):159-198
pubmed: 32739485
J Clin Virol. 2020 Sep;130:104569
pubmed: 32769023
Elife. 2020 Aug 21;9:
pubmed: 32820721
Thorax. 2020 Dec;75(12):1089-1094
pubmed: 32917840
J Clin Virol. 2020 Nov;132:104617
pubmed: 32927358
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Infect Control Hosp Epidemiol. 2021 Nov;42(11):1406-1408
pubmed: 33143811